TY -的T1的功效Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA4669 VL - 54 IS - suppl 63 SP - PA4669 AU - Xia, Yang AU - Huang, Xiu AU - Jin, Rui AU - Li, Wen AU - Shen, Huahao Y1 - 2019/09/28 UR - //www.qdcxjkg.com/content/54/suppl_63/PA4669.abstract N2 - The therapeutic effect of ado-trastuzumab emtansine varies in patients with HER-2-altered lung cancer. We therefore evaluated the efficacy of T-DM1 in treating different subtypes of HER-2 aberrations. We searched for published articles, case reports, and ongoing studies reporting the efficacy of T-DM1 in lung cancer with HER-2 aberrations. Seven studies met the systematic review criteria. The main outcome of these studies was the overall response rate (ORR). Ninety-three patients with various HER-2 aberrations were identified in seven studies. HER-2 upregulation (protein overexpression and/or gene amplification) was more common in patients with a smoking history and adenocarcinoma, with no sex-related differences, whereas HER-2 mutations were more common in female nonsmokers with adenocarcinoma. The ORR for HER-2 aberrations was 19.35%. Subgroup analyses showed an ORR of 35.00% for HER-2 mutation, 42.86% for HER-2 gene amplification, and 2.78% for HER-2 protein overexpression. Notably, the ORR was only 8.33% for HER-2 upregulation but was significantly increased to 46.15% upon concomitant HER-2 upregulation and mutation. Furthermore, the ORR was 25.00% for overexpression plus mutation but up to 80.00% for gene amplification plus overexpression and mutation. T-DM1 is a promising agent targeting HER-2 mutations or amplification in lung cancers, and the therapeutic efficacy may be better for cancers with HER-2 mutation plus amplification. Additional studies of this agent are warranted to confirm the tentative conclusions of this analysis.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4669.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -